Humacyte Inc. (HUMA)
NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HUMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $123.73M
- EPS (TTM)
- -$0.45
- Dividend yield
- None
- 52-week range
- 0.337 – 1.53
- Day range
- 0.4444 – 0.52
- Volume / Avg
- 5.77M / 5.36M
- Beta
- —
- Shares outstanding
- 277.80M
52-week range
HUMA stock today
Humacyte (HUMA) closed at $0.4454 on Nov 20, down 17.90% (-$0.0971), versus the S&P 500's 3.70% decline. Shares are 70.8% below their 52-week high of $1.53, set on Jun 4, 2026 and 32.2% above the 52-week low of $0.337, near the bottom of the past year's range. HUMA is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.5%.
Humacyte has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Humacyte
Company profileHumacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Laura E. Niklason M.D., Ph.D.
- Headquarters
- Durham, NC
- Employees
- 184
- IPO year
- 2020
- Website
- humacyte.com
Financial highlights
Full financialsIn fiscal 2025, Humacyte generated $2.0 million in revenue, up 0.0% from fiscal 2024. Humacyte reported a net loss of $40.8 million, compared with a loss of $148.7 million a year earlier. Gross margin was -376.1% and operating margin -5306.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.04M | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-40.83M | $-148.70M | $-110.78M | $-11.96M | $-26.48M |
| EPS (diluted) | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$1.64+268.21%
- Strong buy 1
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.06 vs $-0.09
- Surprise
- +33.33%
HUMA news
All HUMA news- Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026GlobeNewswire
- Humacyte Q3 Loss Narrows On Lower R&D Costs; Sees Symvess Sales At Least Doubling In Q4NasdaqHUMA, HEI.A
- Humacyte (HUMA) Q3 2026 Earnings Call TranscriptNasdaq
- Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue EstimatesNasdaqHUMA, TECH
- Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial AdoptionGlobeNewswire
- Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026GlobeNewswire
- Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered TissuesGlobeNewswire
- Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months SoonerGlobeNewswire
Humacyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs HUMA |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs HUMA |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs HUMA |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs HUMA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs HUMA |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs HUMA |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs HUMA |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs HUMA |
Indexes, lists and sector
Humacyte stock FAQ
What is Humacyte's stock price today?
HUMA last traded at $0.4454 as of Nov 20, 4:00 PM EST, down 17.90% on the day. Prices are delayed at least 15 minutes.
Who is Humacyte's CEO?
Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc., which has about 184 employees.
What is the HUMA 52-week high?
The 52-week high for HUMA is $1.53 and the 52-week low is $0.337. The stock is currently 70.8% below its high.